Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Oct 29, 2010

Premium

Emerald Biostructures announced this week the formation of its scientific advisory board to which it appointed John Hunt, John McCall, John Mulligan, and Lynn Silver.

Hunt is an associate professor at Columbia University and the co-director of the crystallography group Northeast Structural Genomics. McCall is the president of PharMac and was previously vice president of research at Pfizer and global head of chemistry at Pharmacia and Pharmacia & Upjohn. Mulligan is the founder and former CEO of Blue Heron Biotechnology, which was acquired in August by OriGene. Silver currently works as a consultant in preclinical development and antibacterial discovery for the pharmaceutical industry. Previously, she was a researcher at Merck.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.